

PLATELET AGGREGATION INHIBITORS PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Platelet Aggregation Inhibitors** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	total # of pgs: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
LTC facility contact/phone:		NPI:	MA Provider ID#:
BENEFICIARY INFORMATION		Street address:	
Beneficiary name:		Suite #:	City/State/Zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Non-preferred medication requested:		
<input type="checkbox"/> aspirin/dipyridamole ER capsule	<input type="checkbox"/> Plavix tablet	<input type="checkbox"/> Yosprala tablet <input type="checkbox"/> _____
<input type="checkbox"/> Effient tablet	<input type="checkbox"/> ticlopidine tablet	<input type="checkbox"/> Zontivity tablet
Directions:	Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):		DX code (<i>required</i>):
Non-preferred requests		
1. Does the beneficiary have a history of trial and failure, contraindication, or intolerance to the preferred Platelet Aggregation Inhibitors?	<input type="checkbox"/> Yes – <i>Submit all supporting documentation of medication name(s) and associated trial and failure, intolerance, and contraindications.</i>	
<input type="checkbox"/> Aggrenox capsule <input type="checkbox"/> clopidogrel tablet <input type="checkbox"/> prasugrel tablet	<input type="checkbox"/> No	
<input type="checkbox"/> Brilinta tablet <input type="checkbox"/> dipyridamole tablet		
Zontivity requests		
1. Does the beneficiary have at least one of the following diagnoses? <i>Check all that apply.</i>	<input type="checkbox"/> Yes – <i>Submit documentation of diagnosis.</i>	
<input type="checkbox"/> myocardial infarction (MI) <input type="checkbox"/> peripheral artery disease (PAD)	<input type="checkbox"/> No – <i>Submit medical literature supporting the use of Zontivity for the beneficiary's diagnosis.</i>	
2. Will the beneficiary be taking Zontivity with any of the following medications? <i>Check all that apply.</i>	<input type="checkbox"/> Yes <i>Submit documentation of beneficiary's complete current medication list.</i>	
<input type="checkbox"/> aspirin <input type="checkbox"/> clopidogrel	<input type="checkbox"/> No	
3. Does the beneficiary have any of the following contraindications to Zontivity? <i>Check all that apply.</i>	<input type="checkbox"/> Yes <i>Submit documentation of beneficiary's pertinent medical history</i>	
<input type="checkbox"/> history of stroke <input type="checkbox"/> history of intracranial hemorrhage	<input type="checkbox"/> No	
<input type="checkbox"/> history of transient ischemic attack (TIA) <input type="checkbox"/> active pathological bleeding		
4. Will the beneficiary be taking any of the following medications while taking Zontivity? <i>Check all that apply.</i>	<input type="checkbox"/> Yes <i>Submit documentation of beneficiary's complete current medication list.</i>	
<input type="checkbox"/> anticoagulants <input type="checkbox"/> SSRIs <input type="checkbox"/> strong CYP3A4 inducers	<input type="checkbox"/> No	
<input type="checkbox"/> chronic NSAIDs <input type="checkbox"/> SNRIs <input type="checkbox"/> strong CYP3A4 inhibitors		
5. Does the beneficiary have results of recent liver function tests (LFTs)?	<input type="checkbox"/> Yes <i>Submit results of beneficiary's most recent LFT results</i>	
<input type="checkbox"/> No		

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.